Recent discussions on X about Rani Therapeutics Holdings, Inc. (RANI) have been buzzing with excitement following the announcement of a potential $1.085 billion collaboration with Chugai Pharmaceutical Co. for oral biologics delivery. Many users are highlighting the massive stock surge of over 170% in a single day, attributing it to the deal’s validation of Rani’s innovative RaniPill technology. The conversation is fueled by speculation on whether this momentum can sustain as the market absorbs the news.
Additionally, posts on X point to significant trading volume and a perceived tightening of the stock’s float, with some suggesting that short sellers might be caught off guard by the rapid price increase. There’s a mix of enthusiasm for the company’s clinical progress and curiosity about how much of the narrative around platform validation and cash infusion will drive long-term interest. The focus remains on how this partnership could reshape perceptions of Rani’s future in the biotech space.
Note: This discussion summary was generated from an AI condensation of post data.
Rani Therapeutics Holdings, Inc. Hedge Fund Activity
We have seen 12 institutional investors add shares of Rani Therapeutics Holdings, Inc. stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 3,151,354 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,619,480
- ALPHABET INC. removed 448,492 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $230,480
- CITADEL ADVISORS LLC added 137,349 shares (+inf%) to their portfolio in Q2 2025, for an estimated $70,583
- FOREFRONT WEALTH PARTNERS, LLC removed 65,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $33,403
- BLACKROCK, INC. added 55,069 shares (+86.6%) to their portfolio in Q2 2025, for an estimated $28,299
- WELL DONE, LLC added 52,014 shares (+inf%) to their portfolio in Q2 2025, for an estimated $26,729
- JANNEY MONTGOMERY SCOTT LLC added 28,000 shares (+102.9%) to their portfolio in Q2 2025, for an estimated $14,389
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Rani Therapeutics Holdings, Inc. Analyst Ratings
Wall Street analysts have issued reports on $RANI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 05/16/2025
To track analyst ratings and price targets for Rani Therapeutics Holdings, Inc., check out Quiver Quantitative's $RANI forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
